BLOG

BioProcess Intl

Regeneron to supply Elicio with Libtayo for combo cancer vaccine study

Regeneron has agreed to supply Elicio Therapeutics with the drug Libtayo for clinical trials of its candidate cancer vaccine, ELI-002.